R1 RCM Inc (RCM)vs10X Genomics Inc (TXG)
RCM
R1 RCM Inc
$14.31
0.00%
HEALTHCARE · Cap: $6.04B
TXG
10X Genomics Inc
$47.86
+1.81%
HEALTHCARE · Cap: $6.00B
Smart Verdict
WallStSmart Research — data-driven comparison
R1 RCM Inc generates 286% more annual revenue ($2.46B vs $638.78M). RCM leads profitability with a -2.5% profit margin vs -3.5%. RCM earns a higher WallStSmart Score of 39/100 (F).
RCM
Hold39
out of 100
Grade: F
TXG
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+26.6%
Fair Value
$19.49
Current Price
$14.31
$5.18 discount
Margin of Safety
+68.1%
Fair Value
$60.02
Current Price
$47.86
$12.16 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Operating margin of 3.8%
ROE of -2.2% — below average capital efficiency
Earnings declined 99.3%
0.0% earnings growth
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Revenue declined 2.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : RCM
The strongest argument for RCM centers on Price/Book. Revenue growth of 14.7% demonstrates continued momentum.
Bull Case : TXG
The strongest argument for TXG centers on Debt/Equity.
Bear Case : RCM
The primary concerns for RCM are PEG Ratio, Operating Margin, Return on Equity.
Bear Case : TXG
The primary concerns for TXG are EPS Growth, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
TXG carries more volatility with a beta of 2.04 — expect wider price swings.
RCM is growing revenue faster at 14.7% — sustainability is the question.
RCM generates stronger free cash flow (60M), providing more financial flexibility.
Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RCM scores higher overall (39/100 vs 20/100) and 14.7% revenue growth. TXG offers better value entry with a 68.1% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
R1 RCM Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
R1 RCM Inc (RCM) stands out as a leading provider of technology-driven revenue cycle management solutions, specifically designed to enhance the financial performance of healthcare organizations across the United States. Leveraging cutting-edge analytics and deep industry insights, R1 RCM optimizes billing processes and boosts operational efficiency for hospitals and outpatient facilities. By maximizing revenue capture while improving patient experiences, the company solidifies its position within a rapidly evolving healthcare landscape. With strategic initiatives aimed at expanding its service offerings and increasing market presence, R1 RCM is poised for sustained growth and a competitive edge in the increasingly complex revenue cycle management sector.
10X Genomics Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.
Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?